Trends and variations in mantle cell lymphoma incidence from 1995 to 2013: A comparative study between Texas and National SEER areas-Reference-Cited by-同舟云学术

Trends and variations in mantle cell lymphoma incidence from 1995 to 2013: A comparative study between Texas and National SEER areas

Published:2017-11-03 Issue:68 Volume:8 Page:112516-112529
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Fu Shuangshuang¹,Wang Michael²,Lairson David R.³,Li Ruosha⁴,Zhao Bo⁵,Du Xianglin L.¹

Affiliation:

1. Department of Epidemiology, Human Genetics, and Environmental Science, School of Public Health, The University of Texas Health Science Center in Houston, Houston, Texas 77030, USA

2. Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA

3. Department of Management Policy and Community Health, School of Public Health, The University of Texas Health Science Center in Houston, Houston, Texas 77030, USA

4. Department of Biostatistics, School of Public Health, The University of Texas Health Science Center in Houston, Houston, Texas 77030, USA

5. Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic Role of CDKN2A Deletion and p53 Expression and Association With MIPIb in Mantle Cell Lymphoma;Clinical Lymphoma Myeloma and Leukemia;2023-08

2. Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis;Expert Review of Pharmacoeconomics & Outcomes Research;2023-06-06

3. Treatment Landscape of Relapsed/Refractory Mantle Cell Lymphoma: An Updated Review;Clinical Lymphoma Myeloma and Leukemia;2022-11

4. Mantle cell lymphoma in human immunodeficiency virus ‐infected patients;British Journal of Haematology;2022-10-12

5. Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial;Leukemia;2022-08-13